Immtech Commences Phase IIb Malaria Trial

Immtech International enrollment has begun enrollment in its Phase IIb trial of the oral drug DB289 to treat malaria.

The study will enroll 120 patients with uncomplicated Plasmodium falciparum malaria at the Hospital for Tropical Diseases at Mahidol University, Bangkok, Thailand.

The trial will compare the effectiveness of various three-day dose regimens of DB289 given alone (as monotherapy) and in combination with artesunate (a drug for treating malaria that is extracted from the wormwood plant). For comparison purposes, a separate control group will receive a combination of the drugs artesunate and mefloquin which is the standard treatment for malaria in Thailand. All patients will be treated and monitored for a total of 28 days.